Estimating the Prevalence of GAstrocnemius Muscle REtraction in a Population Suffering From Plantar aPOneurositis and Describing the Effects of Lengthening

NCT ID: NCT07060352

Last Updated: 2025-07-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-09-01

Study Completion Date

2029-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The gastrocnemius muscles, which form the upper part of the calf, can suffer from retraction, a common but often under-diagnosed condition, which can be a risk factor for plantar fasciitis. Retraction can be treated medically, by stretching, or surgically, by lengthening the muscles. Gastrocnemius retraction is difficult to measure, but tests such as the Ankle Dorsiflexion Index (ADI) provide a more accurate assessment.

Knowing the prevalence of this retraction in patients suffering from plantar fasciitis would enable us to improve diagnostic criteria and better target treatments. Surgical lengthening of the gastrocnemius, particularly by tenotomy, is effective in cases of chronic plantar fasciitis, even without apparent muscle retraction.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Plantar Fasciitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ankle Dorsiflexion Index (ADI) measurement

Ankle Dorsiflexion Index (ADI) measurement at D0 and W8

Group Type EXPERIMENTAL

Ankle Dorsiflexion Index (ADI) measurement

Intervention Type DIAGNOSTIC_TEST

Ankle Dorsiflexion Index (ADI) measurement at D0 and W8

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ankle Dorsiflexion Index (ADI) measurement

Ankle Dorsiflexion Index (ADI) measurement at D0 and W8

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient aged 70 or under
* Patient suffering from unilateral plantar fasciitis that has progressed for more than 6 months and is recalcitrant to medical treatment
* Collection of express, oral consent
* Available for follow-up visits

Exclusion Criteria

* Patients with neuropathic pain
* History of fracture of the lower limb, surgery on the lower limb, inflammatory rheumatism of the lower limb, injury to the Achilles tendon
* Patient with another painful orthopedic lesion of the legs/feet
* Patient with surgically treated plantar fasciitis in the year prior to inclusion
* Persons unable to give consent
* Not affiliated to a social security scheme
* Persons under court protection
* Participant in another study with an ongoing exclusion period
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Clinique Saint Charles

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Timothée BISSUEL, MD

Role: CONTACT

+334 78 27 07 97

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2025-A00798-41

Identifier Type: OTHER

Identifier Source: secondary_id

REGAPOP

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

The Effect of Insoles in Plantar Fasciitis
NCT06563492 NOT_YET_RECRUITING NA